Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged biosimilars · clear
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought battle between Amgen and Sanofi in 2021 with the CAFC decision . As a result, at the time, it was said that the attorney…
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed between July 1, 2017, and June 30, 2022. This report's major highlights have been covered in our previous…
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the last five years, from July 1, 2017, through June 30, 2022. Previously, on Patexia 148 , we analyzed the…
Two days ago, the companies that joined forces in order to develop the first Covid vaccine that got approval for emergency use by FDA, Pfizer and BioNTech received news of yet another lawsuit related to the mRNA technology used to develop the vaccine.…
Less than two months ago, Curevac filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech over patent infringement alleging that BioNTech’s Covid-19 vaccine infringed its patents related to mRNA technology. With their…
AMGEN INC. v. HOSPIRA, INC. Before Moore, Bryson, and Chen. Appeal from the United States District Court for the District of Delaware. Summary: Biological engineering activity that would otherwise constitute patent infringement is protected under a safe…
In a recent development with the ongoing complex litigation involving Janssen Biotech’s arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar,(1) Celltrion’s partner Pfizer has filed a suit against Janssen’s…
Written by Daniel A. Kamkar and Agnes Juang, Ph.D. Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar, as required by…
Written by Daniel K. Yarbrough, Ph.D. and Kerry S. Taylor, Ph.D. Bevacizumab (Avastin®) is the subject of the widely watched “patent dance” dispute between Genentech and Amgen regarding Amgen’s proposed biosimilar. Hospira, however,…
Written by Robert J. Hilton, Ph.D. and Jing Liu, Ph.D. On January 13, 2017, the Supreme Court granted certiorari in Amgen v. Sandoz, 794. f. 3d 1347 (Fed. Cir. 2015) and Sandoz v. Amgen, 773 f. 3d 1274 (Fed. Cir. 2014), appealed from the Federal Circuit.…
